Ultragenyx Historical Balance Sheet

RARE Stock

USD 39.18 0.29 0.75%

Trend analysis of Ultragenyx balance sheet accounts such as Other Liabilities of 1.1 B, Property Plant And Equipment Net of 279.2 M, Accounts Payable of 40.7 M or Cash of 202.1 M provides information on Ultragenyx's total assets, liabilities, and equity, which is the actual value of Ultragenyx to its prevalent stockholders. By breaking down trends over time using Ultragenyx balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Ultragenyx latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ultragenyx is a good buy for the upcoming year.

Ultragenyx Inventory

47.26 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.

About Ultragenyx Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Ultragenyx at a specified time, usually calculated after every quarter, six months, or one year. Ultragenyx Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ultragenyx and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ultragenyx currently owns. An asset can also be divided into two categories, current and non-current.

Ultragenyx Balance Sheet Chart

At present, Ultragenyx's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 466.8 M, whereas Net Debt is forecasted to decline to (171.6 M).

Other Current Liab Total Current Liabilities Property Plant And Equipment Net Net Receivables Property Plant And Equipment Gross

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Ultragenyx balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Ultragenyx are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Ultragenyx's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Ultragenyx current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.At present, Ultragenyx's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 466.8 M, whereas Net Debt is forecasted to decline to (171.6 M).

	2022	2023	2024	2025 (projected)
Other Current Liabilities	192.9M	225.7M	295.1M	309.9M
Total Assets	1.5B	1.5B	1.5B	913.5M

Other Current Liab Total Assets

Ultragenyx balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Short Term Investments
Total Assets		0.77	0.81	0.69	0.74	0.8	-0.71	-0.8	0.75	0.74	0.88	0.3	0.79	0.93	0.58	0.94	0.93	0.79	0.93	0.88	0.8	0.75	0.96	0.93	0.72	0.92
Other Current Liab	0.77		1.0	0.29	0.97	0.95	-0.35	-0.99	0.94	0.38	0.93	0.77	0.92	0.6	0.95	0.74	0.86	0.95	0.66	0.97	0.97	0.96	0.67	0.8	0.97	0.72
Total Current Liabilities	0.81	1.0		0.33	0.97	0.97	-0.38	-0.99	0.95	0.42	0.96	0.73	0.93	0.64	0.92	0.77	0.88	0.96	0.71	0.98	0.98	0.97	0.71	0.82	0.97	0.76
Total Stockholder Equity	0.69	0.29	0.33		0.16	0.22	-0.85	-0.29	0.16	0.85	0.43	-0.12	0.34	0.87	0.09	0.66	0.48	0.21	0.73	0.48	0.24	0.17	0.81	0.59	0.14	0.67
Other Liab	0.74	0.97	0.97	0.16		0.98	-0.27	-0.97	0.97	0.31	0.92	0.76	0.9	0.55	0.93	0.68	0.83	0.99	0.63	0.93	0.99	0.98	0.62	0.75	0.99	0.7
Property Plant And Equipment Net	0.8	0.95	0.97	0.22	0.98		-0.27	-0.97	0.98	0.33	0.96	0.67	0.95	0.61	0.86	0.73	0.86	0.99	0.71	0.93	0.99	0.99	0.65	0.78	0.98	0.75
Net Debt	-0.71	-0.35	-0.38	-0.85	-0.27	-0.27		0.33	-0.19	-1.0	-0.42	0.06	-0.28	-0.82	-0.19	-0.58	-0.49	-0.31	-0.63	-0.48	-0.33	-0.21	-0.83	-0.54	-0.2	-0.56
Retained Earnings	-0.8	-0.99	-0.99	-0.29	-0.97	-0.97	0.33		-0.96	-0.37	-0.96	-0.75	-0.93	-0.61	-0.93	-0.78	-0.9	-0.97	-0.71	-0.98	-0.98	-0.97	-0.68	-0.84	-0.98	-0.74
Accounts Payable	0.75	0.94	0.95	0.16	0.97	0.98	-0.19	-0.96		0.24	0.92	0.68	0.89	0.54	0.86	0.73	0.84	0.97	0.68	0.92	0.98	0.97	0.61	0.79	0.98	0.74
Cash	0.74	0.38	0.42	0.85	0.31	0.33	-1.0	-0.37	0.24		0.47	-0.03	0.33	0.84	0.23	0.6	0.52	0.36	0.66	0.52	0.38	0.27	0.85	0.57	0.25	0.59
Non Current Assets Total	0.88	0.93	0.96	0.43	0.92	0.96	-0.42	-0.96	0.92	0.47		0.62	0.96	0.73	0.81	0.83	0.91	0.94	0.83	0.97	0.95	0.95	0.76	0.86	0.93	0.81
Non Currrent Assets Other	0.3	0.77	0.73	-0.12	0.76	0.67	0.06	-0.75	0.68	-0.03	0.62		0.65	0.08	0.91	0.31	0.5	0.69	0.17	0.66	0.7	0.73	0.17	0.4	0.77	0.28
Other Assets	0.79	0.92	0.93	0.34	0.9	0.95	-0.28	-0.93	0.89	0.33	0.96	0.65		0.65	0.82	0.74	0.85	0.9	0.74	0.92	0.92	0.95	0.65	0.78	0.93	0.74
Cash And Short Term Investments	0.93	0.6	0.64	0.87	0.55	0.61	-0.82	-0.61	0.54	0.84	0.73	0.08	0.65		0.37	0.86	0.78	0.6	0.92	0.74	0.61	0.55	0.98	0.82	0.52	0.9
Net Receivables	0.58	0.95	0.92	0.09	0.93	0.86	-0.19	-0.93	0.86	0.23	0.81	0.91	0.82	0.37		0.56	0.73	0.88	0.43	0.87	0.89	0.89	0.47	0.65	0.92	0.52
Common Stock Total Equity	0.94	0.74	0.77	0.66	0.68	0.73	-0.58	-0.78	0.73	0.6	0.83	0.31	0.74	0.86	0.56		0.94	0.72	0.9	0.85	0.73	0.69	0.9	0.99	0.68	0.9
Common Stock Shares Outstanding	0.93	0.86	0.88	0.48	0.83	0.86	-0.49	-0.9	0.84	0.52	0.91	0.5	0.85	0.78	0.73	0.94		0.85	0.85	0.92	0.86	0.84	0.84	0.96	0.83	0.85
Non Current Liabilities Total	0.79	0.95	0.96	0.21	0.99	0.99	-0.31	-0.97	0.97	0.36	0.94	0.69	0.9	0.6	0.88	0.72	0.85		0.68	0.93	1.0	0.98	0.66	0.77	0.98	0.74
Other Current Assets	0.93	0.66	0.71	0.73	0.63	0.71	-0.63	-0.71	0.68	0.66	0.83	0.17	0.74	0.92	0.43	0.9	0.85	0.68		0.8	0.69	0.66	0.9	0.87	0.63	0.9
Other Stockholder Equity	0.88	0.97	0.98	0.48	0.93	0.93	-0.48	-0.98	0.92	0.52	0.97	0.66	0.92	0.74	0.87	0.85	0.92	0.93	0.8		0.95	0.93	0.79	0.89	0.93	0.82
Total Liab	0.8	0.97	0.98	0.24	0.99	0.99	-0.33	-0.98	0.98	0.38	0.95	0.7	0.92	0.61	0.89	0.73	0.86	1.0	0.69	0.95		0.99	0.68	0.79	0.99	0.75
Property Plant And Equipment Gross	0.75	0.96	0.97	0.17	0.98	0.99	-0.21	-0.97	0.97	0.27	0.95	0.73	0.95	0.55	0.89	0.69	0.84	0.98	0.66	0.93	0.99		0.6	0.75	0.99	0.71
Total Current Assets	0.96	0.67	0.71	0.81	0.62	0.65	-0.83	-0.68	0.61	0.85	0.76	0.17	0.65	0.98	0.47	0.9	0.84	0.66	0.9	0.79	0.68	0.6		0.87	0.58	0.91
Common Stock	0.93	0.8	0.82	0.59	0.75	0.78	-0.54	-0.84	0.79	0.57	0.86	0.4	0.78	0.82	0.65	0.99	0.96	0.77	0.87	0.89	0.79	0.75	0.87		0.74	0.88
Property Plant Equipment	0.72	0.97	0.97	0.14	0.99	0.98	-0.2	-0.98	0.98	0.25	0.93	0.77	0.93	0.52	0.92	0.68	0.83	0.98	0.63	0.93	0.99	0.99	0.58	0.74		0.69
Short Term Investments	0.92	0.72	0.76	0.67	0.7	0.75	-0.56	-0.74	0.74	0.59	0.81	0.28	0.74	0.9	0.52	0.9	0.85	0.74	0.9	0.82	0.75	0.71	0.91	0.88	0.69

Click cells to compare fundamentals

Ultragenyx Account Relationship Matchups

Ultragenyx balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.8B	1.5B	1.5B	1.5B	1.5B	913.5M
Other Current Liab	140.9M	134.5M	192.9M	225.7M	295.1M	309.9M
Total Current Liabilities	189.6M	181.4M	261.2M	280.4M	344.2M	361.4M
Total Stockholder Equity	1.2B	922.6M	352.5M	275.4M	255.3M	466.8M
Other Liab	348.7M	376.3M	387.6M	911.9M	1.0B	1.1B
Property Plant And Equipment Net	114.0M	176.2M	285.7M	290.6M	265.9M	279.2M
Net Debt	(665.3M)	(265.6M)	(101.4M)	(170.4M)	(163.4M)	(171.6M)
Retained Earnings	(1.6B)	(2.1B)	(2.8B)	(3.4B)	(4.0B)	(3.8B)
Accounts Payable	12.9M	17.1M	43.3M	42.1M	38.8M	40.7M
Cash	713.5M	307.6M	132.9M	213.6M	173.7M	202.1M
Non Current Assets Total	464.3M	665.8M	661.5M	758.8M	686.3M	720.6M
Non Currrent Assets Other	(24.5M)	11.6M	10.7M	57.7M	197.7M	207.6M
Other Assets	3.5M	8.8M	20.6M	16.8M	19.4M	20.3M
Cash And Short Term Investments	1.2B	999.1M	896.7M	577.2M	610.0M	552.6M
Net Receivables	23.1M	28.4M	40.4M	73.4M	121.8M	127.9M
Common Stock Total Equity	58K	67K	69K	70K	80.5K	44.1K
Common Stock Shares Outstanding	60.8M	67.8M	69.9M	73.5M	90.5M	54.4M
Liabilities And Stockholders Equity	1.8B	1.5B	1.5B	1.5B	1.5B	913.5M
Non Current Liabilities Total	415.6M	418.5M	931.7M	935.2M	897.0M	941.9M
Other Current Assets	57.6M	71.7M	68.9M	47.6M	40.3M	35.2M
Other Stockholder Equity	2.8B	3.0B	3.1B	3.7B	4.2B	4.4B
Total Liab	605.2M	599.8M	1.2B	1.2B	1.2B	1.3B
Property Plant And Equipment Gross	114.0M	226.2M	349.1M	374.0M	378.4M	397.3M
Total Current Assets	1.3B	856.6M	883.9M	732.2M	817.1M	588.6M
Accumulated Other Comprehensive Income	689K	(1.4M)	(6.6M)	647K	(643K)	(675.2K)
Common Stock	67K	69K	70K	82K	92K	51.5K
Property Plant Equipment	74.7M	73.5M	141.2M	259.7M	298.7M	313.6M
Short Term Investments	488.0M	432.6M	614.8M	363.6M	436.3M	358.3M
Net Tangible Assets	480.4M	978.9M	758.4M	148.0M	170.2M	161.7M
Retained Earnings Total Equity	(1.4B)	(1.6B)	(2.1B)	(2.8B)	(2.5B)	(2.4B)
Capital Surpluse	2.1B	2.8B	3.0B	3.1B	3.6B	2.0B
Inventory	13.0M	16.2M	26.8M	34.0M	45.0M	47.3M
Non Current Liabilities Other	382.3M	385.2M	4.8M	12.2M	17.1M	16.2M
Intangible Assets	131.1M	130.8M	160.1M	166.3M	178.3M	116.6M
Long Term Investments	10.5M	258.9M	154.5M	199.9M	135.0M	112.1M
Net Invested Capital	1.2B	922.6M	352.5M	275.4M	255.3M	460.6M
Net Working Capital	1.1B	675.2M	622.7M	451.7M	473.0M	649.3M
Capital Stock	67K	69K	70K	82K	92K	76.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Ultragenyx is a strong investment it is important to analyze Ultragenyx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ultragenyx's future performance. For an informed investment choice regarding Ultragenyx Stock, refer to the following important reports:

How To Invest In Ultragenyx

Details

Is Ultragenyx Stock a good investment?

Details

What is Ultragenyx's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.29)

Revenue Per Share

6.188

Quarterly Revenue Growth

0.294

Return On Assets

(0.22)

Return On Equity

(2.12)

The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ultragenyx Historical Balance Sheet

Ultragenyx Inventory

47.26 Million

About Ultragenyx Balance Sheet Analysis

Ultragenyx Balance Sheet Chart

Total Current Liabilities

Property Plant And Equipment Net

Ultragenyx balance sheet Correlations

Ultragenyx Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ultragenyx balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Other Current Liab
Total Liab	+ 1.0	Non Current Liabilities Total
Non Current Liabilities Total	+ 0.99	Other Liab
Total Liab	+ 0.99	Other Liab
Property Plant Equipment	+ 0.99	Other Liab
Non Current Liabilities Total	+ 0.99	Property Plant And Equipment Net

Cash	- 1.0	Net Debt
Retained Earnings	- 0.99	Total Current Liabilities
Retained Earnings	- 0.99	Other Current Liab
Property Plant Equipment	- 0.98	Retained Earnings
Total Liab	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings